Substance,Type of TRV,TRV Value,Study Details,"Threshold/
Non-threshold
Endpoint",TRV Derivation Method,"Critical
Effect(s)","Carcinogenicity
Classification",Source
Ethylbenzene,Oral TDI,"2.2E-02
mg/kg -day
BW","Study Type: chronic
Species: B6C3F1 mice
Mode of Administration: inhalation
(whole body exposure chambers)
Exposure Regime: 0, 75, 250, or
750 ppm (0, 330, 1100, or 3300 mg/m3)
for 6 hours/day, 5 days/week
Duration: 103 weeks
Uncertainty Factors: 25 (10 for
intraspecies variability and 2.5 for
interspecies variability)","NOAEL = 330 mg/m3
(75 ppm)","Estimated mouse internal
liver concentration
corresponding to NOAEL =
0.08 mg/L
+
PBPK model to obtain
external oral dose that
is relevant in humans
= 0.54 mg/kg -day
BW
TDI = human external
oral dose/UF","Pituitary gland
toxicity
(hyperplasia)
and
Hepatotoxicity
(cellular alterations
of the liver)","CEPA: see 2016
CMP assessment
(ECCC and
HC, 2016)
IARC: Group 2B
possibly
carcinogenic
to humans
(IARC, 2000)
US EPA IRIS:
Group D
not classifiable
as to human
carcinogenicity
(US EPA, 1998e)","HC, 2014b
(based on
NTP 1999)"
Ethylbenzene,Inhalation TC,"2.0E+00
mg/m3","Study Type: chronic
Species: male and female F344/N rats
and B6C3F1 mice
Mode of Administration: inhalation
Exposure Regime: 0, 75, 250, or
750 ppm (0, 330, 1100, or 3300 mg/m3),
6 hours/day, 5 days/week
Duration: 104 weeks (rats);
103 weeks (mice)
Uncertainty Factors: 30 (10 for
intraspecies variability and 3 for
interspecies variability)","NOAEL = 75 ppm
(330 mg/m3)","NOAEL adjusted for
continuous exposure
NOAEL = 57 mg/m3
adj
TC = NOAEL /UF
adj","Pituitary gland
toxicity
(hyperplasia)
and
Hepatotoxicity
(liver cellular
alterations and
necrosis)",,"HC, 2018a
(based on
OEHHA, 2000
[derived from
NTP, 1999 and
Chan et al., 1998])"
